Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Econazole · Ecoza

Small molecule · Inhibitor of 14-alpha demethylase (CYP51A1) · developed by Resilia Pharmaceuticals

Approved FDA

1 Registered trials

What is Econazole?

Econazole is an imidazole antifungal that inhibits 14-alpha demethylase, blocking ergosterol synthesis in fungal cell walls. This compromises cell wall integrity and increases permeability, leading to cellular leakage.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Ecoza
Drug type: Small molecule
Targets: 14-alpha demethylase (CYP51A1)
Mechanism: Inhibitor of 14-alpha demethylase (CYP51A1)
Pathways: ergosterol biosynthesis
Therapy area: Dermatology
Developer: Resilia Pharmaceuticals, Inc.
In trials of: ABEO
FDA status: Approved as Ecoza, NDA205175 · FDA label
UNII: H18Z54707C

✅ FDA-approved uses

Interdigital tinea pedis

From the indications section of the FDA label (version of Dec 4, 2023). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT00385502	Phase 2	Onychomycosis	Completed	ABEO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Onychomycosis

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z